Caplin Point Laboratories

As of 2026-11-06, CAPLIPOINT trades at ₹2381.70, reflecting a mixed technical posture across timeframes. The daily trend is bearish, with price trading below the 20-period and 50-period EMAs and the Supertrend indicator signaling downside pressure. Despite this short-term weakness, the stock remains above its 20-period SMA and 200-period SMA, suggesting longer-term support holds. Conversely, the monthly chart shows a bullish structure, with price above all supplied moving averages and the Supertrend, indicating a broader upward bias that contrasts with recent daily declines.

Momentum is developing but not yet decisive; the daily ADX stands at 22.22, while the weekly ADX is slightly stronger at 24.26. Volatility is elevated, with annualized volatility at +38.4% and an ATR of 3.37%. The stock is currently positioned in the middle of its 20-day (+51.3%) and 252-day (+59.2%) ranges, having pulled back from recent highs. Key resistance lies near ₹2388–₹2405, while immediate support is found at ₹2366. An active monthly Inside Bar pattern suggests consolidation, awaiting direction.

Caplin Point Laboratories Limited has scheduled its Board of Directors meeting for November 12, 2026, to approve unaudited financial results for the quarter and half-year ended September 30, 2026. The company will host a virtual conference call with analysts and institutional investors on the same day at 4:30 PM IST to discuss performance. In compliance with SEBI insider trading regulations, the trading window for Designated Persons and their immediate relatives is closed from October 1, 2026, to November 14, 2026.

As of November 6, 2026, the stock closed at ₹2,381.70, reflecting a -1.6% daily decline and an -11.1% one-month return. Technical indicators show a bearish daily trend with the price trading below key moving averages, while the monthly trend remains bullish. The stock carries an annualized volatility of +38.4% and is currently in a -16.9% drawdown from recent highs. Shareholding data as of September 30, 2026, indicates promoters hold 70.57% of the equity, with the public holding 29.43%.

Caplin Point Laboratories Limited has scheduled its Board Meeting for November 12, 2026, to approve unaudited financial results for Q2 and H1 FY2027. Following the results, an earnings conference call is set for the same day at 4:30 PM IST. Shareholding data as of September 30, 2026, indicates promoters hold 70.57% of equity, with the public holding 29.43%. Governance stability was reinforced at the 35th Annual General Meeting on September 25, 2026, where shareholders approved the re-appointment of Dr. Sridhar Ganesan as Managing Director (98.94%), continuation of Mr. C. C. Paarthipan as Chairman (98.72%), and appointment of Mr. D. Muralidharan as Whole-Time Director (96.78%). A trading window closure for designated persons runs from October 1 to November 16, 2026, in compliance with insider trading regulations.

Caplin Point Laboratories demonstrates robust earnings growth and strong cash generation, though recent balance-sheet metrics signal a shift in working-capital efficiency. For the trailing twelve months (TTM) ending around November 2026, sales reached ₹2,287 crore with an 18% compounded profit growth rate over three years. Net profit for TTM stood at ₹678 crore, up from ₹650 crore in FY2026, while EPS rose to ₹87.53. Operating profit margin remained healthy, with operating profit of ₹797 crore against sales of ₹2,287 crore.

Cash flow quality is a standout feature: CFO/EBITDA conversion improved to 87% in FY2026, and Cash from Operating Activities surged to ₹523 crore, significantly outpacing investing outflows of ₹582 crore. The company maintains a debt-free profile, with borrowings stable around ₹221 crore and interest expenses negligible at ₹1 crore TTM. However, working-capital efficiency has deteriorated; the Cash Conversion Cycle widened to 194 days in Mar 2026 from 175 days in Mar 2025, driven by a rise in Debtor Days to 138 days and Inventory Days to 181 days. Return on Capital Employed (ROCE) dipped slightly to 24% in FY2026 from 26% in prior years, reflecting the impact of increased investments (₹859 crore) and fixed assets (₹580 crore).

The most critical checkpoint is whether the expansion in receivables and inventory stabilizes as new capacities come online, ensuring that rising sales translate into sustained free cash flow rather than trapped working capital.

Technical indicators for Caplin Point Laboratories on November 6, 2026, signal a near-term bearish environment despite longer-term bullish trends. The daily Supertrend is bearish, supported by a negative slope in both the 20-day EMA (-5.07) and SMA (-59.67). On the weekly timeframe, the Supertrend also remains bearish with a steep negative EMA slope (-60.73), suggesting sustained selling pressure over recent weeks. Price action reflects this weakness, with the stock closing at ₹2,381.70, down from the previous close of ₹2,421.40. The stock has experienced a significant current drawdown of -16.9% from its peak, following a maximum historical drawdown of -41.7%. Short-term returns are negative across multiple horizons: -1.6% over one day, -6.6% over 20 days, and -11.1% over one month. While the monthly trend remains bullish (Supertrend direction: bullish), the divergence between short-term technical breakdowns and longer-term momentum highlights elevated volatility, evidenced by an annualized volatility of +38.4% and an ATR of 3.37%. Immediate resistance is tight at ₹2,388.13, while support lies lower at ₹2,366.07.